Abstract
The therapeutic efficacy and tolerance of ergoferon, an antiviral medication combining anti-inflammatory and antihistaminic actions were estimated in the treatment of adult patients with influenza and acute respiratory viral infection. Ergoferon was shown to stimulate production of endogenous interferon-alpha and interferon-gamma and to normalize the T-lymphocyte subpopulation composition and histamine level, that made it possible to lower the time of the disease clinical signs development and to prevent typical complications and chronic somatic pathology exacerbation.
Publication types
-
Randomized Controlled Trial
MeSH terms
-
Acute Disease
-
Adolescent
-
Adult
-
Antibodies / immunology
-
Antibodies / therapeutic use*
-
Antiviral Agents / immunology
-
Antiviral Agents / therapeutic use*
-
CD4-CD8 Ratio
-
CD4-Positive T-Lymphocytes / drug effects
-
CD4-Positive T-Lymphocytes / immunology
-
CD8-Positive T-Lymphocytes / drug effects
-
CD8-Positive T-Lymphocytes / immunology
-
Female
-
Histamine Antagonists / immunology
-
Histamine Antagonists / therapeutic use
-
Humans
-
Influenza, Human / drug therapy*
-
Influenza, Human / immunology
-
Interferon Inducers / immunology
-
Interferon Inducers / therapeutic use*
-
Interferon-alpha / biosynthesis
-
Interferon-gamma / biosynthesis
-
Killer Cells, Natural / drug effects
-
Killer Cells, Natural / immunology
-
Male
-
Middle Aged
-
Respiratory Tract Infections / drug therapy*
-
Respiratory Tract Infections / immunology
-
Young Adult
Substances
-
Antibodies
-
Antiviral Agents
-
Histamine Antagonists
-
Interferon Inducers
-
Interferon-alpha
-
ergoferon
-
Interferon-gamma